Distribution and clinical significance of anti-TIF1-γ autoantibody isotypes and IgG subclasses in patients with dermatomyositis
4 affiliations
- 1Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- 2Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- 3Department of General Surgery, Shanghai Minimally Invasive Surgery Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- 4Department of Otolaryngology & Head and Neck Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Abstract
Objectives Anti-transcriptional intermediary factor 1-γ (TIF1-γ) antibody is strongly associated with cancer in patients with dermatomyositis (DM), yet the clinical relevance of its isotypes and IgG subclasses remains unclear. This study aimed to evaluate the prognostic value of anti-TIF1-γ isotypes and IgG subclasses for cancer risk and mortality in patients with DM.Methods Serum samples from 95 patients with anti-TIF1-γ-positive DM were analysed for anti-TIF1-γ isotypes (IgG, IgA, IgM) and IgG subclasses (IgG1–4) using ELISA. Clinical data were collected retrospectively. Multivariable Cox proportional regression was used to identify factors associated with mortality.Results Among the 95 patients with anti-TIF1-γ-positive DM, 54 (56.84%) were diagnosed with cancer and 14 died from cancer. Positivity rates were 100.0% for isotypes IgG of anti-TIF1-γ, 49.5% for IgA and 0.0% for IgM. For IgG subclasses, positivity rates were IgG1 93.7%, IgG2 53.7%, IgG3 97.9% and IgG4 51.6%. The most frequent antibody profiles were IgG1+IgG2+IgG3+IgA+ (21.1%), IgG1+IgG3+IgG4+ (21.1%), IgG1+IgG2+IgG3+IgG4+ (15.8%) and IgG1+IgG3+IgA+ (13.7%). Cancer incidence was 100% (36/36) in patients with an IgA+/IgG4⁻ profile vs 10.53% (4/38) in those with an IgA⁻/IgG4+ profile. IgG4 was negatively associated with cancer, whereas IgA showed a strong positive association (both p<0.001). Multivariable analysis confirmed that the absence of anti-TIF1-γ IgG4 and the presence of anti-TIF1-γ IgA were associated with increased mortality.Conclusions The combination of anti-TIF1-γ IgA positivity and IgG4 negativity may serve as biomarkers for stratifying cancer risk and predicting mortality in patients with anti-TIF1-γ-positive DM.
Related
- Review on the significance and clinical application of anti-p53 autoantibody detection
- Clinical Significance and Distribution of Cerebrospinal Fluid Type IV Oligoclonal Band Pattern in Neurological Disorders: A Retrospective Analysis
- Establishment of an Anti-Nephrin Autoantibody Assay and the Predictive and Diagnostic Significance of Pre-treatment Antibody Titers in Pediatric Nephrotic Syndrome
- Efgartigimod in the treatment of severe Guillain–Barre syndrome with overlapping autoantibody syndrome: a case report and updated clinical review
- Non-HLA Autoantibody-Driven Lung Allograft Injury, Clinical Course, Autoantibody Profiling, and Response to Steroid and Belatacept
BibTeX
@article{zheng2026distribution,
title = {{Distribution and clinical significance of anti-TIF1-γ autoantibody isotypes and IgG subclasses in patients with dermatomyositis}},
author = {Jie Zheng and Hao Li and Jing Sun and Qian Zhao and Feng Xue and Hua Cao and Junyi Hu and Jiaming Teng and Kaile He and Zhenru Liu and Mingyu Ye and Yanting Shih and Licheng Diao and Xinlin Shao and Jichang Wu},
journal = {RMD Open},
year = {2026},
month = nov,
doi = {10.1136/rmdopen-2026-007293},
url = {https://doi.org/10.1136/rmdopen-2026-007293},
note = {CC BY},
}
RIS
TY - JOUR
TI - Distribution and clinical significance of anti-TIF1-γ autoantibody isotypes and IgG subclasses in patients with dermatomyositis
AU - Jie Zheng
AU - Hao Li
AU - Jing Sun
AU - Qian Zhao
AU - Feng Xue
AU - Hua Cao
AU - Junyi Hu
AU - Jiaming Teng
AU - Kaile He
AU - Zhenru Liu
AU - Mingyu Ye
AU - Yanting Shih
AU - Licheng Diao
AU - Xinlin Shao
AU - Jichang Wu
PY - 2026
DA - 2026/11/08
JO - RMD Open
DO - 10.1136/rmdopen-2026-007293
UR - https://doi.org/10.1136/rmdopen-2026-007293
AB - Objectives Anti-transcriptional intermediary factor 1-γ (TIF1-γ) antibody is strongly associated with cancer in patients with dermatomyositis (DM), yet the clinical relevance of its isotypes and IgG subclasses remains unclear. This study aimed to evaluate the prognostic value of anti-TIF1-γ isotypes and IgG subclasses for cancer risk and mortality in patients with DM.Methods Serum samples from 95 patients with anti-TIF1-γ-positive DM were analysed for anti-TIF1-γ isotypes (IgG, IgA, IgM) and IgG subclasses (IgG1–4) using ELISA. Clinical data were collected retrospectively. Multivariable Cox proportional regression was used to identify factors associated with mortality.Results Among the 95 patients with anti-TIF1-γ-positive DM, 54 (56.84%) were diagnosed with cancer and 14 died from cancer. Positivity rates were 100.0% for isotypes IgG of anti-TIF1-γ, 49.5% for IgA and 0.0% for IgM. For IgG subclasses, positivity rates were IgG1 93.7%, IgG2 53.7%, IgG3 97.9% and IgG4 51.6%. The most frequent antibody profiles were IgG1+IgG2+IgG3+IgA+ (21.1%), IgG1+IgG3+IgG4+ (21.1%), IgG1+IgG2+IgG3+IgG4+ (15.8%) and IgG1+IgG3+IgA+ (13.7%). Cancer incidence was 100% (36/36) in patients with an IgA+/IgG4⁻ profile vs 10.53% (4/38) in those with an IgA⁻/IgG4+ profile. IgG4 was negatively associated with cancer, whereas IgA showed a strong positive association (both p<0.001). Multivariable analysis confirmed that the absence of anti-TIF1-γ IgG4 and the presence of anti-TIF1-γ IgA were associated with increased mortality.Conclusions The combination of anti-TIF1-γ IgA positivity and IgG4 negativity may serve as biomarkers for stratifying cancer risk and predicting mortality in patients with anti-TIF1-γ-positive DM.
SN - 2056-5933
ER -